Names | |
---|---|
IUPAC name
scyllo-Inositol
[1]
| |
Systematic IUPAC name
(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexol | |
Other names
Scyllitol; Cocositol; Quercinitol; AZD 103; 1,3,5/2,4,6-Hexahydroxycyclohexane; scyllo-Cyclohexanehexol
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.113.358 |
EC Number |
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C6H12O6 | |
Molar mass | 180.156 g·mol−1 |
Appearance | White crystalline solid |
Melting point | 348.5 to 350 °C (659.3 to 662.0 °F; 621.6 to 623.1 K) |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
scyllo-Inositol is one of the stereoisomers of inositol. It is also known as scyllitol, cocositol, quercinitol, and 1,3,5/2,4,6-hexahydroxycyclohexane. scyllo-Inositol is a naturally occurring plant sugar alcohol found most abundantly in coconut palm. [2]
Researchers at the University of Toronto have found that scyllo-inositol can block the development of amyloid-beta (Aβ) plaques in the brains of transgenic mice. [3] scyllo-Inositol also reversed memory deficits, and alleviated other symptoms associated with the accumulation of Aβ proteins in these mice. [4]
Researchers at the Harvard Medical School-affiliated McLean Hospital found that chronic users of anabolic steroids had lower levels of brain scyllo-Inositol levels than non-users. [5]
This article needs to be updated. The reason given is: The result of the 2009 clinical trial is not reported.(June 2024) |
scyllo-Inositol was investigated by Transition Therapeutics as a disease-modifying therapy for Alzheimer's disease under the designation AZD-103. A patent was issued on April 21, 2009 ( U.S. patent 7,521,481) claiming the use of scyllo-inositol for treating Alzheimer's disease. [6] scyllo-Inositol underwent clinical investigation as an orally-administered therapeutic agent for the treatment of mild to moderate Alzheimer's disease. It had received fast track designation from the U.S. Food and Drug Administration. Transition has partnered with Elan Corporation on the development of the compound under the designation ELND005. ELND005 was in a Phase 2 clinical study, which completed enrollment in October 2008. The study was a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 353 patients with mild to moderate Alzheimer's disease. The planned treatment period for each patient was approximately 18 months.
In December 2009, Elan and Transition jointly reported that the study has been modified so that only the 250 mg twice daily dose will be continued because of greater rates of adverse events, including 9 deaths, in the higher dose groups (1000 mg and 2000 mg dosed twice daily). [7] Although the clinical trial helped establish the safety profile, the removal of the higher dose groups reduced the power of the study to establish efficacy. [8]